The benefit varied widely based on individual risk tiers ranging from five fewer deaths in the lowest-risk patients to 48 fewer deaths in the highest-risk groups. ... All articles from the June 11, 2021, ACP Diabetes Monthly Newsletter.
Taspoglutide, 20 mg; once-weekly exenatide; and dulaglutide, 1.5 mg, also reduced body weight. ... All articles from the December 11, 2015, ACP Diabetes Monthly Newsletter.
Using data from the Diabetes Control and Complications Trial and its follow-up study, they assessed regularly scheduled fundus photographs obtained from about 1,400 patients from 1983 through 2012. ... All articles from the May 12, 2017, ACP Diabetes
From 2015 to 2019, the percentage of patients treated with an SGLT2 inhibitor increased from 3.8% to 11.9%. ... All articles from the May 14, 2021, ACP Diabetes Monthly Newsletter.
Ultimately, although some uncertainty remains, [this study] provides encouraging evidence of the real-world safety of SGLT-2 inhibitors, allowing patients to benefit from their use with greater confidence in their ... All articles from the August 9, 2019,
stage kidney disease, doubling of creatinine, or death from renal causes) (HR, 0.66; 95% CI, 0.53 to 0.81; P<0.001) with the drug. ... All articles from the May 10, 2019, ACP Diabetes Monthly Newsletter.
https://diabetes.acponline.org/archives/2015/08/14/8.htm. ACP has partnered with the American College of Cardiology to participate in the Diabetes Collaborative Registry, a national clinical diabetes registry ... ACP has partnered with the American
Glargine, 300 U/mL (Glar-300), had a favorable weight profile compared with degludec, 100 U/mL (Deg-100); degludec, 200 u/mL (Deg-200); thrice-weekly degludec (Deg-3TW); glargine, ... wrote. All articles from the July 13, 2018, ACP Diabetes Monthly
likelihood of hypoglycemia to such an extent that the benefits from long-acting analogs compared with NPH insulin are lost,” the study authors noted. ... All articles from the March 12, 2021, ACP Diabetes Monthly Newsletter.
Results were published online on Sept. 28 by Gut. This study included 176,050 women from the NHS (n=80,500) and NHS II (n=95,550) and 28,639 men ... All articles from the October 9, 2020, ACP Diabetes Monthly Newsletter.